CD70 and neoplasm: In preclinical studies, anti-CD70 antibodies demonstrated indirect anti-tumor efficacy mediated by NK cells and macrophages involving antibody-dependent cellular cytotoxicity and tumor cell phagocytosis, respectively, as we have similarly recently reported using the clinically-approved anti-epidermal growth factor receptor antibody cetuximab [22,35].